Search
tumor necrosis factor receptor superfamily member 17; CD269; B-cell maturation protein (TNFRSF17, BCM, BCMA, CD269)
Function:
- receptor for TNFSF13B/BLyS/BAFF & TNFSF13/APRIL
- promotes B-cell survival
- role in regulation of humoral immunity
- activates NF-kappa-B & JNK
- associates with TRAF1, TRAF2, TRAF3, TRAF5 & TRAF6
Structure: contains 1 TNFR-Cys repeat
Compartment:
- single-pass type 3 membrane protein
- plasma membrane, endomembrane system
- perinuclear Golgi-like structures
Expression:
- expressed in mature B-cells & plasma cells, including multiple myeloma cells
- not expressed in T- cells or monocytes
Pathology:
- chromosomal translocation t(4;16)(q26;p13) involving TNFRSF17 with IL2 is found in T-cell acute lymphoblastic leukemia (T-ALL)
Pharmacology:
- target for multiple myeloma CAR T-cell therapy [2]
General
cluster-of-differentiation antigen; cluster designation antigen; CD antigen
tumor necrosis factor [TNF] receptor family
Properties
SIZE: entity length = 184 aa
MW = 20 kD
COMPARTMENT: cell nucleus
golgi
MOTIF: breakpoint {3-4}
TNFR-Cys {7-41}
MOTIF: cysteine residue {C8}
MODIFICATION: cysteine residue {C21}
cysteine residue {C21}
MODIFICATION: cysteine residue {C8}
cysteine residue {C24}
MODIFICATION: cysteine residue {C37}
cysteine residue {C28}
MODIFICATION: cysteine residue {C41}
cysteine residue {C37}
MODIFICATION: cysteine residue {C24}
cysteine residue {C41}
MODIFICATION: cysteine residue {C28}
transmembrane domain {55-77}
Database Correlations
OMIM 109545
UniProt Q02223
Pfam PF09257
Entrez Gene 608
Kegg hsa:608
References
- UniProt :accession Q02223
- Fuerst ML
CAR T-Cell Therapy Shows Durable Activity in Heavily Pretreated
Multiple Myeloma. B-cell maturation antigen most promising
myeloma target for CAR T-cell therapy.
MedPage Today. ASCO Reading Room. Feb 1, 2018
https://www.medpagetoday.com/reading-room/asco/immunotherapy/70885
- Cohen AD, Garfall AL, Stadtmauer EA et al
505 Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-
Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with
Cyclophosphamide Conditioning for Refractory Multiple Myeloma
(MM).
ASH 59th Annual Meeting. Dec 9-12, 2017
https://ash.confex.com/ash/2017/webprogram/Paper106279.html
- NIEHS-SNPs
http://egp.gs.washington.edu/data/tnfrsf17/